Dermatology Medical News about Dermatofibrosarcoma, imatinib

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Doctors and the DEA Free full text

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Neoadjuvant imatinib therapy for dermatofibrosarcoma protuberans
Archives of Dermatology, 07/27/09

Han A et al. - In a study to evaluate retrospective data obtained from 4 pts with locally advanced or recurrent dermatofibrosarcoma protuberans (DFSP) who received neoadjuvant imatinib mesylate therapy before undergoing Mohs micrographic surgery, it appears that neoadjuvant imatinib therapy is a well-tolerated, novel approach to DFSP that reduces tumor burden and facilitates resection.

Methods

Retrospective data were evaluated that was obtained from 4 pts with locally advanced or recurrent DFSP who received neoadjuvant imatinib mesylate therapy before undergoing Mohs micrographic surgery.

Results

Pts treated with neoadjuvant imatinib therapy had an average tumor size reduction of 36.9%.
This clinical response was paralleled by histopathologic changes, including decreased cellularity in 100% of the total area as well as significant hyalinization.
Imatinib therapy for DFSP before Mohs micrographic surgery was associated with 100% local control at maximum follow-up of 4 yrs.

<< Previous
Surgical treatment of rhinophyma

Next >>
Granuloma Annulare Treated With Rifampin, Ofloxacin, and...

Improved early event-free survival with imatinib in philadelphia chromosome-positive acute lymphoblastic leukemia: a childrens oncology group study
Journal of Clinical Oncology, 10/09/09 Relevance Score: 48%

Healthcare resource utilization and costs associated with non-adherence to imatinib treatment in chronic myeloid leukemia patients
Current Medical Research and Opinion, 11/17/09 Relevance Score: 46%

Rare incidence of congestive heart failure in gastrointestinal stromal tumor and other sarcoma patients receiving imatinib mesylate
Cancer, 11/06/09 Relevance Score: 44%

Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final results of the CSTIBES02 trial
Haematologica, 10/07/09 Relevance Score: 43%

Phase II Study of Neoadjuvant Imatinib in Glioblastoma: Evaluation of Clinical and Molecular Effects of the Treatment
Clinical Cancer Research, 10/01/09 Relevance Score: 43%